Literature DB >> 26022440

Stat1-Deficient Mice Are Not an Appropriate Model for Efficacy Testing of Recombinant Vesicular Stomatitis Virus-Based Filovirus Vaccines.

Andrea Marzi1, Lisa Kercher2, Joshua Marceau3, Anthony York1, Julie Callsion1, Donald J Gardner2, Thomas W Geisbert4, Heinz Feldmann1.   

Abstract

Stat1(-/-) mice lack a response to interferon α, β, and γ, allowing for replication of nonadapted wild-type (wt) Ebolavirus and Marburgvirus. We sought to establish a mouse model for efficacy testing of live attenuated recombinant vesicular stomatitis virus (rVSV)-based filovirus vaccine vectors using wt Ebolavirus and Marburgvirus challenge strains. While infection of immunocompetent mice with different rVSV-based filovirus vectors did not cause disease, infection of Stat1(-/-) mice with the same vectors resulted in systemic infection and lethal outcome for the majority of tested rVSVs. Despite differences in viral loads, organ tropism was remarkably similar between rVSV filovirus vaccine vectors and rVSVwt, with the exception of the brain. In conclusion, Stat1(-/-) mice are not an appropriate immunocompromised mouse model for efficacy testing of live attenuated, replication-competent rVSV vaccine vectors. Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2015. This work is written by (a) US Government employee(s) and is in the public domain in the US.

Entities:  

Keywords:  Ebolavirus; Marburgvirus; Stat1-deficient mice; Vesicular stomatitis virus; vaccine

Mesh:

Substances:

Year:  2015        PMID: 26022440      PMCID: PMC4564544          DOI: 10.1093/infdis/jiv188

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  11 in total

1.  Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses.

Authors:  Michael Garbutt; Ryan Liebscher; Victoria Wahl-Jensen; Steven Jones; Peggy Möller; Ralf Wagner; Viktor Volchkov; Hans-Dieter Klenk; Heinz Feldmann; Ute Ströher
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

2.  Enforced viral replication activates adaptive immunity and is essential for the control of a cytopathic virus.

Authors:  Nadine Honke; Namir Shaabani; Giuseppe Cadeddu; Ursula R Sorg; Dong-Er Zhang; Mirko Trilling; Karin Klingel; Martina Sauter; Reinhard Kandolf; Nicole Gailus; Nico van Rooijen; Christoph Burkart; Stephan E Baldus; Melanie Grusdat; Max Löhning; Hartmut Hengel; Klaus Pfeffer; Masato Tanaka; Dieter Häussinger; Mike Recher; Philipp A Lang; Karl S Lang
Journal:  Nat Immunol       Date:  2011-11-20       Impact factor: 25.606

3.  Vesicular Stomatitis Virus-Based Vaccines for Prophylaxis and Treatment of Filovirus Infections.

Authors:  Andrea Marzi; Heinz Feldmann; Thomas W Geisbert; Darryl Falzarano
Journal:  J Bioterror Biodef       Date:  2011-09-25

4.  Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy.

Authors:  Andrea Marzi; Hideki Ebihara; Julie Callison; Allison Groseth; Kinola J Williams; Thomas W Geisbert; Heinz Feldmann
Journal:  J Infect Dis       Date:  2011-11       Impact factor: 5.226

5.  Filovirus infection of STAT-1 knockout mice.

Authors:  JoLynne Raymond; Steven Bradfute; Mike Bray
Journal:  J Infect Dis       Date:  2011-11       Impact factor: 5.226

6.  The differential interferon responses of two strains of Stat1-deficient mice do not alter susceptibility to HSV-1 and VSV in vivo.

Authors:  Sarah Katzenell; Yufei Chen; Zachary M Parker; David A Leib
Journal:  Virology       Date:  2014-01-14       Impact factor: 3.616

7.  Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses.

Authors:  Steven M Jones; Heinz Feldmann; Ute Ströher; Joan B Geisbert; Lisa Fernando; Allen Grolla; Hans-Dieter Klenk; Nancy J Sullivan; Viktor E Volchkov; Elizabeth A Fritz; Kathleen M Daddario; Lisa E Hensley; Peter B Jahrling; Thomas W Geisbert
Journal:  Nat Med       Date:  2005-06-05       Impact factor: 53.440

8.  Recombinant vesicular stomatitis viruses from DNA.

Authors:  N D Lawson; E A Stillman; M A Whitt; J K Rose
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-09       Impact factor: 11.205

9.  Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever.

Authors:  Steven M Jones; Ute Stroher; Lisa Fernando; Xianggou Qiu; Judie Alimonti; Pasquale Melito; Mike Bray; Hans-Dieter Klenk; Heinz Feldmann
Journal:  J Infect Dis       Date:  2007-11-15       Impact factor: 5.226

10.  Durability of a vesicular stomatitis virus-based marburg virus vaccine in nonhuman primates.

Authors:  Chad E Mire; Joan B Geisbert; Krystle N Agans; Benjamin A Satterfield; Krista M Versteeg; Elizabeth A Fritz; Heinz Feldmann; Lisa E Hensley; Thomas W Geisbert
Journal:  PLoS One       Date:  2014-04-23       Impact factor: 3.240

View more
  14 in total

1.  Therapeutic DNA Vaccines for Human Papillomavirus and Associated Diseases.

Authors:  Max A Cheng; Emily Farmer; Claire Huang; John Lin; Chien-Fu Hung; T-C Wu
Journal:  Hum Gene Ther       Date:  2018-03-16       Impact factor: 5.695

Review 2.  The use of mice lacking type I or both type I and type II interferon responses in research on hemorrhagic fever viruses. Part 2: Vaccine efficacy studies.

Authors:  Marko Zivcec; Christina F Spiropoulou; Jessica R Spengler
Journal:  Antiviral Res       Date:  2020-01-22       Impact factor: 5.970

3.  Mucin-Like Domain of Ebola Virus Glycoprotein Enhances Selective Oncolytic Actions against Brain Tumors.

Authors:  Xue Zhang; Tingting Zhang; John N Davis; Andrea Marzi; Anthony M Marchese; Michael D Robek; Anthony N van den Pol
Journal:  J Virol       Date:  2020-03-31       Impact factor: 5.103

4.  Pseudovirus rVSVΔG-ZEBOV-GP Infects Neurons in Retina and CNS, Causing Apoptosis and Neurodegeneration in Neonatal Mice.

Authors:  Ian L McWilliams; Jennifer L Kielczewski; Derek D C Ireland; Jacob S Sykes; Aaron P Lewkowicz; Krishnamurthy Konduru; Biying C Xu; Chi-Chao Chan; Rachel R Caspi; Mohanraj Manangeeswaran; Daniela Verthelyi
Journal:  Cell Rep       Date:  2019-02-12       Impact factor: 9.423

5.  Efficacy of Vesicular Stomatitis Virus-Ebola Virus Postexposure Treatment in Rhesus Macaques Infected With Ebola Virus Makona.

Authors:  Andrea Marzi; Patrick W Hanley; Elaine Haddock; Cynthia Martellaro; Gary Kobinger; Heinz Feldmann
Journal:  J Infect Dis       Date:  2016-08-05       Impact factor: 5.226

6.  Non-neutralizing antibodies elicited by recombinant Lassa-Rabies vaccine are critical for protection against Lassa fever.

Authors:  Tiago Abreu-Mota; Katie R Hagen; Kurt Cooper; Peter B Jahrling; Gene Tan; Christoph Wirblich; Reed F Johnson; Matthias J Schnell
Journal:  Nat Commun       Date:  2018-10-11       Impact factor: 14.919

7.  Vesicular Stomatitis Virus-Based Vaccine Protects Mice against Crimean-Congo Hemorrhagic Fever.

Authors:  Sergio E Rodriguez; Robert W Cross; Karla A Fenton; Dennis A Bente; Chad E Mire; Thomas W Geisbert
Journal:  Sci Rep       Date:  2019-05-23       Impact factor: 4.379

8.  Protection Against Marburg Virus Using a Recombinant VSV-Vaccine Depends on T and B Cell Activation.

Authors:  Andrea Marzi; Andrea R Menicucci; Flora Engelmann; Julie Callison; Eva J Horne; Friederike Feldmann; Allen Jankeel; Heinz Feldmann; Ilhem Messaoudi
Journal:  Front Immunol       Date:  2019-01-22       Impact factor: 7.561

9.  Ebola Virus Glycoprotein Domains Associated with Protective Efficacy.

Authors:  Bharti Bhatia; Wakako Furuyama; Thomas Hoenen; Heinz Feldmann; Andrea Marzi
Journal:  Vaccines (Basel)       Date:  2021-06-10

10.  A VSV-based Zika virus vaccine protects mice from lethal challenge.

Authors:  Jackson Emanuel; Julie Callison; Kimberly A Dowd; Theodore C Pierson; Heinz Feldmann; Andrea Marzi
Journal:  Sci Rep       Date:  2018-07-23       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.